Since cell trafficking is a multistep process involving the concerted interaction of cell adhesion molecules binding to their respective ligands as well as chemokine-regulated migration pathways, our study was designed to assess the effects of epratuzumab on the expression of a range of adhesion molecules (CD62L, β1 integrin and β7 integrin) and migration towards CXCL12, CXCL13 and a number of CXCR3 ligands (CXCL9, 10 and 11) on peripheral blood mononuclear cells (PBMCs) from SLE patients. Here, CXCL9 is linked to systemic lupus erythematosus.